TrialNet: University of Florida Clinical Center and Network

描述（由申请人提供）：佛罗里达大学是DPT-1和国际糖尿病试验网络（1型糖尿病TrialNet）的创始成员，为TrialNet和1型糖尿病（T1 D）做出了重大而重要的贡献，它是表现最好的临床中心之一。TrialNet的主要目标是通过测试针对减少β细胞破坏和/或增强β细胞存活的干预措施，预防和/或延迟T1 D在有患病风险的人群中的发展。佛罗里达大学寻求继续作为临床中心作为TrialNet网络的一部分。美国国立卫生研究院TrialNet RFA计划通过资助必要的基础设施，继续为高生产率的中心提供支持，这些基础设施将能够筛查大量T1 D亲属，以识别那些有临床疾病风险的人。继续TrialNet会员资格将使我们建立和非常成功的佛罗里达大学临床中心及其强大的附属网络，以继续支持受试者招募到研究，提高试验性能，受试者保留和随访。事实上，我们的中心准备继续寻求未来的预防和逆转T1 D通过其出色的环境和创新的研究人员与成熟的方法，每个致力于确定一种方法来预防/治愈疾病，以及加强招募和保留T1 D临床试验。针对本RFA，本申请描述了：1）机构对TrialNet和T1 D领域的独特优势和贡献; 2）识别和维护活跃的附属网络的持续和新颖策略; 3）招募、外展和协作计划; 4）提高成本效率的策略; 5）绩效监控; 6）考虑联合IRB; 7）未来T1 D临床研究人员的发展; 8）当前和未来5年预防T1 D的潜在机遇和挑战。

DESCRIPTION (provided by applicant): The University of Florida, a founding member of the DPT-1 and the internationally constituted diabetes trial network (Type 1 Diabetes TrialNet), has made significant and important contributions to TrialNet and type 1 diabetes (T1D), where it participates as one of the top performing Clinical Centers. The primary goal of TrialNet is to prevent and/or delay the development of T1D in persons at risk for the disease by testing interventions targeted at decreasing �-cell destruction and/or enhancing �-cell survival. The University of Florida seeks to continue serving as a Clinical Center as part of the TrialNet network. The NIH TrialNet RFA intends to continue providing support for highly productive centers by funding the necessary infrastructure that would enable screening large numbers of T1D relatives so as to identify those at risk of clinical disease. Continuing TrialNet membership would enable our established and highly successful University of Florida Clinical Center and its strong Affiliate network to continue supporting subject recruitment into studies, enhancing trial performance, subject retention, and follow-up. Indeed, our Center is poised to continue the quest for the future prevention and reversal of T1D through its outstanding environment and innovative investigators with proven approaches, each dedicated to identifying a means to prevent/cure the disease as well as to enhance recruitment and retention for T1D clinical trials. In responding to this RFA, this application describes: 1) Unique strengths and contributions of the institution to TrialNet and the T1D field; 2) Ongoing and novel strategies to identify and maintain an active Affiliate network; 3) Recruitment, outreach, and collaboration plans; 4) Strategies to enhancing cost efficiency; 5) Performance monitoring; 6) Consideration of federated IRB; 7) Development of future T1D clinical researchers; and 8) Potential opportunities and challenges for the prevention of T1D currently and over the next 5 years.